GB1603244A - Medicaments for the suppression of pathological processes - Google Patents

Medicaments for the suppression of pathological processes Download PDF

Info

Publication number
GB1603244A
GB1603244A GB18751/78A GB1875178A GB1603244A GB 1603244 A GB1603244 A GB 1603244A GB 18751/78 A GB18751/78 A GB 18751/78A GB 1875178 A GB1875178 A GB 1875178A GB 1603244 A GB1603244 A GB 1603244A
Authority
GB
United Kingdom
Prior art keywords
fibrinogen
injection
plasma
carrageenan
rat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB18751/78A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19772722769 external-priority patent/DE2722769C3/de
Priority claimed from DE2750920A external-priority patent/DE2750920C3/de
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of GB1603244A publication Critical patent/GB1603244A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB18751/78A 1977-05-20 1978-05-10 Medicaments for the suppression of pathological processes Expired GB1603244A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19772722769 DE2722769C3 (de) 1977-05-20 1977-05-20 Verwendung von Fibrinogen
DE2750920A DE2750920C3 (de) 1977-11-15 1977-11-15 Verwendung von Fibrinopeptiden A und B

Publications (1)

Publication Number Publication Date
GB1603244A true GB1603244A (en) 1981-11-18

Family

ID=25772044

Family Applications (1)

Application Number Title Priority Date Filing Date
GB18751/78A Expired GB1603244A (en) 1977-05-20 1978-05-10 Medicaments for the suppression of pathological processes

Country Status (4)

Country Link
US (1) US4215109A (cg-RX-API-DMAC7.html)
JP (1) JPS5417107A (cg-RX-API-DMAC7.html)
CH (1) CH644762A5 (cg-RX-API-DMAC7.html)
GB (1) GB1603244A (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5104639A (en) * 1980-01-14 1992-04-14 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders using electrochromatography
US6333160B1 (en) 1988-08-31 2001-12-25 Keiji Tamura Method and specific diagnostic system for objectively assessing and monitoring the relative homeostasis and health of animals
ES2114654T3 (es) 1993-06-08 1998-06-01 Vertex Pharma Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.
US7605132B2 (en) * 2001-08-29 2009-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
US7528227B2 (en) * 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3973001A (en) * 1954-04-27 1976-08-03 Solco Basel Ag Tissue cell stimulating blood extracts
US2847348A (en) * 1954-05-27 1958-08-12 Ortho Pharma Corp Plasma fractionation and product therefrom
US2847349A (en) * 1954-05-27 1958-08-12 Ortho Pharma Corp Plasma preparation
US3466368A (en) * 1967-06-02 1969-09-09 Us Health Education & Welfare Cleavage of human gamma globulin by means of cyanogen bromide
AT275038B (de) * 1967-11-15 1969-10-10 Immuno Ag Verfahren zur Gewinnung von reinem Blutalbumin aus Hämopigmente enthaltenden Proteinlösungen
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
US3664994A (en) * 1969-06-30 1972-05-23 Upjohn Co Process for separating horse gamma globulin fractions by chromatography
US3763135A (en) * 1971-11-08 1973-10-02 Baxter Laboratories Inc Gamma globulin production from cohn fraction iii using polyethylene glycol
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3808189A (en) * 1973-03-15 1974-04-30 American Cyanamid Co Isolation of gamma globulin preparations enriched in iga and igm using polyethylene glycol
US3893990A (en) * 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene
US3893991A (en) * 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US3973002A (en) * 1974-04-12 1976-08-03 E. R. Squibb & Sons, Inc. Antihemophilic factor
JPS5176418A (en) * 1974-12-26 1976-07-02 Teijin Ltd Menekiguroburinno seizoho
DE2500076C3 (de) * 1975-01-02 1982-11-18 SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld Verfahren zur Gewinnung von intravenös-verträglichen Gammaglobulinen
CA1064396A (en) * 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4087415A (en) * 1976-06-09 1978-05-02 William L. Wilson Antithrombin III
US4081432A (en) * 1977-07-25 1978-03-28 Monsanto Company Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers

Also Published As

Publication number Publication date
CH644762A5 (de) 1984-08-31
JPS6341890B2 (cg-RX-API-DMAC7.html) 1988-08-19
JPS5417107A (en) 1979-02-08
US4215109A (en) 1980-07-29

Similar Documents

Publication Publication Date Title
Holmberg et al. Genetic variants of von Willebrand's disease
Laki et al. Chemistry and physiology of the fibrinogen-fibrin transition
Green Spontaneous inhibitors of factor VIII
Schorer et al. Lupus anticoagulant induces a selective defect in thrombin‐mediated endothelial prostacyclin release and platelet aggregation
Kiley et al. Acute renal failure: Eighty cases of renal tubular necrosis
Lindsay et al. Reduction of thrombus formation on dialyser membranes by aspirin and RA 233
Ackroyd The immunological basis of purpura due to drug hypersensitivity
Corcos et al. Neutrophilic agranulocytosis during administration of penicillamine
Rosenau A study of the cause of sudden death following the injection of horse serum
Wilkins et al. Immunologically mediated thrombocytopenia in the dog
Rosenberg et al. A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenaemia
Milner et al. Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII.
Horowitz et al. Acquired hemophilia due to a circulating anticoagulant: Report of two cases, with review of the literature
US4215109A (en) Medicaments for the suppression of pathological processes
Wellde et al. Presenting features of Rhodesian sleeping sickness patients in the Lambwe Valley, Kenya
Olsen Intracranial surgery in hemophiliacs: report of a case and review of the literature
Bertoli et al. Does hypercoagulability exist in CAPD patients?
Ceriello et al. Metabolic control may alter antithrombin III activity but not its plasma concentration in diabetes: a possible role for nonenzymatic glycosylation
Swineford Jr et al. Phenylbutazone toxicity: depression of erythropoiesis
Gans et al. Problems in hemostasis during open heart surgery. IX. Changes observed in the plasminogen-plasmin system and their significance for therapy
Parry et al. Familial haemostatic defect associated with reduced prothrombin consumption
Wüthrich et al. Allergic urticaria and angioedema caused by a hemostatic sponge of bovine fibrin used in tooth extraction
Mackenzie et al. Rapid renal failure in a case of multiple myeloma: the role of Bence Jones proteins
Fahey et al. Effect of dicumarol on Ac-globulin and prothrombin activity.
Aylward et al. Plasma L-tryptophan concentrations in chronic rheumatic diseases and the effects of some antirheumatic drugs on the binding of the amino-acid to plasma proteins in vivo and in vitro

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee